Allworth Financial’s PMV Pharmaceuticals PMVP Stock Holding History

Allworth Financial’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-39	Closed	-$187	–	3350
2023 Q1	$187	Buy	+39	New	+$274	﹤0.01%	3020

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Allworth Financial's PMVP Position: Q2 2023 in Review

Allworth Financial sold out of PMV Pharmaceuticals (PMVP) in Q2 2023, closing a stake of 39 shares — an estimated $187 sold.

Allworth Financial first reported a position in PMVP in Q1 2023 and held it in 1 quarter. The position peaked at $187 in Q1 2023. 106 funds tracked by Wall St. Rank hold PMVP as of Q2 2023.

Allworth Financial reported no remaining PMV Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Allworth Financial sold 39 PMV Pharmaceuticals shares in Q2 2023, an estimated $187.
Allworth Financial first reported a position in PMV Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Allworth Financial's PMV Pharmaceuticals position peaked at $187 in Q1 2023.
106 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2023.

Based on Allworth Financial's 13F filing for Q2 2023, filed 18 Jul 2023.